Filing Flows › Akebia Therapeutics (AKBA) › Recalls, complaints & regulation
Akebia Therapeutics (AKBA): clinical trials
Akebia Therapeutics (AKBA) beyond its filings: 3 active clinical trials.
Akebia Therapeutics' latest quarter
Akebia Therapeutics, Q3 2026: revenue $36.9M (-37% year over year), operating margin -31.1%, net loss $14.4M, operating cash flow $2.3M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Akebia Therapeutics have?
3 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.